Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$199.9MBeat by $253.0K
EPS$1.92Beat by $0.20
Revenue estimate$199.6M
EPS estimate$1.72
“In the second quarter, we saw strong demand across our ADHD portfolio, highlighted by record-high JORNAY PM prescriptions and prescriber adoption, alongside 41% revenue growth. Importantly, we have completed the acquisition of AZSTARYS and our integration is progressing well, with our expanded salesforce fully trained and deployed ahead of the important back-to-school season. In addition, our pain portfolio continues to provide a solid base for our business despite increased pressure on Nucynta franchise revenues. Together, our differentiated ADHD portfolio and established pain business provide a strong foundation for growth and long-term value creation. As we move into the second half of the year, we are focused on three key strategic priorities: driving growth in our ADHD business, maximizing the value of our pain portfolio, and strategically deploying capital to create long-term shareholder value.”
Vikram Karnani

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$218.0M
EPS estimate$1.80

Financials

Q2 2026

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$722.41M-35.5%
Enterprise value$577M-41.6%
P/E15.1×-15.8×
P/S0.9×-0.7×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0×0.0×
Current ratio1×-0.2×

Segments

By product

See full
Belbuca$57.7M+9.6%
Jornay PM$46.1M+41.2%
Xtampza ER$45.0M—
Nucynta ER$15.7M-21.2%
Nucynta IR$14.4M-45.8%

By segment

See full
Segment$199.9M+6.3%

FAQ

When did Collegium Pharmaceutical, Inc. report Q2 2026 earnings?
Collegium Pharmaceutical, Inc. (COLL) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Collegium Pharmaceutical, Inc.'s Q2 2026 revenue and EPS?
Collegium Pharmaceutical, Inc. reported revenue of $199.9M and eps of $1.92 for Q2 2026.
Did Collegium Pharmaceutical, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $199.6M by $253.0K. EPS beat the consensus estimate of $1.72 by $0.20.
How did Collegium Pharmaceutical, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.3% from $188.0M a year earlier and eps grew 14.3% from $1.68.
Where can I find Collegium Pharmaceutical, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-053849) and the 10-Q periodic report (0001628280-26-053851) directly on SEC EDGAR. The filing index links above go to sec.gov.